ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1963

Phenome Wide Association Study of IL6R Variant Identifies Drug Target for Cardiovascular Disease and Inflammation

Tianxi Cai1,2,3, Yichi Zhang1,3, Yuk-Lam Ho1, Nicholas Link1, Jiehuan Sun1,3, Jie Huang1,4, Tianrun Cai1,2,4, Scott Damrauer5, Yuri Ahuja2, Jacqueline Honerlaw1, Jie Huang1, Lauren Costa1, Petra Schubert1, Chuan Hong3, David Gagnon1,6, Yan Sun7, Michael Gaziano1,2,4, Peter Wilson7,8, Kelly Cho1,2,4, Philip Tsao9, Christopher J. O'Donnell1,2 and Katherine P. Liao1,2,4, 1VA Boston Healthcare System, Boston, MA, 2Harvard Medical School, Boston, MA, 3Harvard T.H. Chan School of Public Health, Boston, MA, 4Brigham and Women's Hospital, Boston, MA, 5Corporal Michael Crescenz VA Medical Center, Perlman School of Medicine, University of Pennsylvania, Philadelphia, PA, 6Boston University School of Public Health, Boston, MA, 7Emory University Schools of Medicine and Public Health, Atlanta, GA, 8Atlanta VA Medical Center, Atlanta, GA, 9VA Palo Alto Health Care System, Department of Medicine, Stanford University School of Medicine, Stanford, CA

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Bioinformatics, C Reactive Protein, cardiovascular disease and phenotypes, IL-6

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 23, 2018

Title: Genetics, Genomics and Proteomics Poster

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Individuals with an interleukin 6 receptor (IL6R) genetic variant not on IL6R blocking therapy have biomarker profiles similar to those treated with IL6R blockers.  Individuals with the IL6 variant have impaired IL6 signaling due to reduced IL6Rs; the goal of IL6R blockade is also to impair IL6 signaling by binding to IL6R.  This gene-drug pair may therefore facilitate whether the IL6R variant has an association with a reduced risk for a phenotype, which in turn can inform which diseases may benefit from treatment with IL6R blockade.  To test this hypothesis, we performed a Phenome-Wide Association Study (PheWAS) to screen for associations between an IL6R genetic variant and a broad range of phenotypes in the electronic health records (EHR).

Methods: We studied veteran participants in the Veteran’s Affairs Million Veteran’s Project using genomic data linked to EHR.  We extracted all diagnoses codes and mapped them to phenotype groups using published PheWAS methods. Routine laboratory measurements, e.g. complete blood count, were also extracted.  A PheWAS was performed by constructing logistic regression models testing associations between the IL6R variant (Asp358Ala, rs2228145) and 1,342 phenotype groups; linear regression models were constructed to screen for associations between IL6R and 26 routine laboratory measurements.  All models were adjusted for age, sex, population stratification, and healthcare utilization.  Significance was reported using false discovery rate ≤0.05; data for Bonferroni adjustments also provided.  We replicated findings using freely available online data from the Vanderbilt University Biobank (BioVU) and the UK Biobank, two biobanks with linked genetic and EHR data.

Results:   We studied 330,374 participants; the minor allele frequency of the IL6R variant was 35.3%.  IL6R was most strongly associated with a reduced risk of aortic aneurysm phenotypes (OR 0.87-0.90, 95% CI 0.84, 0.93) (Figure).  We observed the expected association between IL6R and reduced C-reactive protein.  We also observed known effects of IL6R blockade from clinical trials, increased hemoglobin.  The protective effect of the IL6R variant for aortic aneurysm and coronary heart disease was replicated in BioVU and the UK Biobank, respectively.

Conclusion: In this proof of concept study, we demonstrated the application of the PheWAS using large EHR biobanks to potentially inform drug effects.  The findings of a protective effect of a single IL6R variant with aortic aneurysms corresponded with the newest indication for IL6R blockade for giant cell arteritis, where clinical manifestation is aortic aneurysm.

 


Disclosure: T. Cai, None; Y. Zhang, None; Y. L. Ho, None; N. Link, None; J. Sun, None; J. Huang, None; T. Cai, None; S. Damrauer, None; Y. Ahuja, None; J. Honerlaw, None; J. Huang, None; L. Costa, None; P. Schubert, None; C. Hong, None; D. Gagnon, None; Y. Sun, None; M. Gaziano, None; P. Wilson, None; K. Cho, None; P. Tsao, None; C. J. O'Donnell, None; K. P. Liao, None.

To cite this abstract in AMA style:

Cai T, Zhang Y, Ho YL, Link N, Sun J, Huang J, Cai T, Damrauer S, Ahuja Y, Honerlaw J, Huang J, Costa L, Schubert P, Hong C, Gagnon D, Sun Y, Gaziano M, Wilson P, Cho K, Tsao P, O'Donnell CJ, Liao KP. Phenome Wide Association Study of IL6R Variant Identifies Drug Target for Cardiovascular Disease and Inflammation [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/phenome-wide-association-study-of-il6r-variant-identifies-drug-target-for-cardiovascular-disease-and-inflammation/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/phenome-wide-association-study-of-il6r-variant-identifies-drug-target-for-cardiovascular-disease-and-inflammation/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology